Dermato - Cosmetic Products
Unique, natural, multi-active and highly effective dermato-cosmetic products
Products Effect Status Partnering
Epi MA
serum		 reduces acne and blemishes
fades hyperpigmented spots
brightens skin tone & texture
protects skin from air pollution
and UV damage		 notified in EU
on the market in China
and CH		 available for out-
licensing
Epi MA-T
cream		 calms itching and dermatitis
prone skin
protects skin from inflammation
regenerates skin
restores skin health		 ready for market launch available for out-
licensing
Epi DA
serum		 rejuvenates, tightens, lifts skin
corrects fine lines and wrinkles
protects skin from air pollution
and UV damage		 ready for market launch available for out-
licensing
Epi SP
cream		 protects against sunburn and
skin inflammation
regenerates skin		 in development available for out-
licensing

EpiPharm AG: Pipeline 3/2025

Epi MA: The Lead Product
Epi MA multi-active serum with outstanding efficacy designed to address
different skin disorders

Multi-acting & multi-benificial
designed to address different skin disorders

  • remarkable reduction of akne marks and hyperpigmentations
  • effectively restores blemished skin and stimulates skin regeneration
  • shows strong anti-pollution, anti-inflammatory and anti-bacterial effect
  • acts against «skin growth disorders» (e.g. actinic keratosis)
  • significantly increases skin density and elasticity (antiaging erffect)

Before Treatment

After Treatment

Outstanding efficacy

  • demonstrated by clinical studies
  • confirmed by product users (case series)
High quality - swiss made
  • developed and produced in Switzerland
  • 100% natural & vegan

Seborrheic Keratois (SK) - Projects
First SK therapy that treats tumor formation and growth
 

SK treated with Epi-SK17

Dermoscopic image - Lesion clearance after treatment

EPI-SK 14, a phase I/II study with Artemether has successfully been completed. The data demonstrate a clinically relevant and statistically significant regression of SK lesions in size, color and texture. Regression continued markedly after treatment stop. The study results have been published online in the British Journal of Dermatology.

EPI-SK17 has been selected as lead product candidate based on properties which distinguish it from other artemisinin derivatives tested, including greater potency, and shorter duration of treatment. The product is about to enter phase IIb clinical development.

Before Treatment

After Treatment

EPI-N06 - Project
Effective and lasting treatment of hyperpigmented spots
 

Age spot treatead with Epi-N06

Dermoscopic image – Significant regression in size and color

EPI-N06 is a topical, novel and effective treatment of melanocytic pigmented lesions which targets the melanin formation by synergistic mechanisms of action and by different pathways.
A phase I/II study has successfully been completed in melanocytic pigmented lesions (nevi and age spots) without tolerability issues. Data demonstrated clinically relevant regression of lesions size and color and a marked reduction of melanin in the epidermis.

Before Treatment

After Treatment

Confocal microscopy image – Relevant decrease of fluorescent melanin